Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity
Joanna Kovalski, Goksu Sarioglu, Vishvak Subramanyam, et al.
Nature Cell Biology (2025)
Closed Access | Times Cited: 2
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Macroautophagy/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis
Leng Han, Lingjun Meng, Jiao Liu, et al.
Cancer Letters (2024) Vol. 604, pp. 217258-217258
Open Access | Times Cited: 5
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Two Cysteines in Raf Kinase Inhibitor Protein Make Differential Contributions to Structural Dynamics In Vitro
Hyun Sang Cho, Mohammad Faysal Al Mazid, Eun‐Young Lee, et al.
Molecules (2025) Vol. 30, Iss. 2, pp. 384-384
Open Access
Predictive biomarkers of pancreatic cancer metastasis: A comprehensive review
Mengting Chen, Hongsen Liu, Yufei Xiao, et al.
Clinica Chimica Acta (2025), pp. 120176-120176
Closed Access
Regulating MYC translation in cancer
Zainab Hussain, Mara H. Sherman
Nature Cell Biology (2025)
Closed Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 704-704
Open Access
Artificial intelligence in tumor drug resistance: Mechanisms and treatment prospects
Jianyou Gu, Junfeng Zhang, Silüe Zeng, et al.
(2025)
Closed Access
Adapting systems biology to address the complexity of human disease in the single-cell era
David S. Fischer, Martin Arreola Villanueva, Peter Winter, et al.
Nature Reviews Genetics (2025)
Closed Access
Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer
Dennis Gong, Rachel Liu, Yi Cui, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
New exploration of KRASG12D inhibitors and the mechanisms of resistance
Yinghong Li, Junfeng Zhao, Yintao Li
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
Jianzhuang Wu, Kexin Xie, Yixuan Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
The Persistent Power of the Taxane/Platin Chemotherapy
Lucy B. Xu, Elizabeth R. Smith, Vasili Koutouratsas, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1208-1208
Open Access
Pancreatic Cancer: Pathogenesis and Clinical Studies
Kexun Zhou, Yingping Liu, Chuanyun Tang, et al.
MedComm (2025) Vol. 6, Iss. 4
Open Access
The future of tumor organoids in precision therapy
Seok-Young Kim, Marc van de Wetering, Hans Clevers, et al.
Trends in cancer (2025)
Open Access
Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells
Thomas Sevrin, Hiroaki Imoto, Sarah A. Robertson, et al.
Cell Reports (2024) Vol. 43, Iss. 9, pp. 114710-114710
Open Access | Times Cited: 4
Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer
Andrew J. Aguirre, Ben Z. Stanger, Anirban Maitra
Cancer Research (2024) Vol. 84, Iss. 18, pp. 2950-2953
Closed Access | Times Cited: 4
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Unravelling the complexities of resistance mechanism in pancreatic cancer: insights from in vitro and ex-vivo model systems
Giulia Lencioni, Alessandro Gregori, Belen Toledo B, et al.
Seminars in Cancer Biology (2024)
Open Access | Times Cited: 3
MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis
Chungui Xu, Weihao Lin, Qi Zhang, et al.
Molecular Medicine (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 2
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Baofa Yu, Shengwen Shao, Wenxue Ma
Cancer Letters (2024), pp. 217350-217350
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top